{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:44:25Z","timestamp":1789764265865,"version":"4.0.1"},"publisher-location":"New York, NY","reference-count":115,"publisher":"Springer US","isbn-type":[{"value":"9781461406525","type":"print"},{"value":"9781461406532","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/978-1-4614-0653-2_14","type":"book-chapter","created":{"date-parts":[[2012,3,12]],"date-time":"2012-03-12T12:35:13Z","timestamp":1331555713000},"page":"172-188","source":"Crossref","is-referenced-by-count":14,"title":["Machado-Joseph Disease and other Rare Spinocerebellar Ataxias"],"prefix":"10.1007","author":[{"given":"Antoni","family":"Matilla-Due\u00f1as","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"14_CR1","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/brain\/awl081","volume":"129","author":"A Matilla-Due\u00f1as","year":"2006","unstructured":"Matilla-Due\u00f1as A, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain 2006; 129:1357\u20131370.","journal-title":"Brain"},{"issue":"2","key":"14_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12311-009-0144-2","volume":"9","author":"A Matilla-Due\u00f1as","year":"2010","unstructured":"Matilla-Due\u00f1as A, Sanchez I, Corral-Juan M et al. Cellular and Molecular Pathways Triggering Neurodegeneration in the Spinocerebellar Ataxias. Cerebellum 2010; 9(2):148\u2013166.","journal-title":"Cerebellum"},{"issue":"3","key":"14_CR3","first-page":"203","volume":"29","author":"P Coutinho","year":"1981","unstructured":"Coutinho P, Sequeiros J. Clinical, genetic and pathological aspects of Machado-Joseph disease. J Genet Hum 1981; 29(3):203\u2013209.","journal-title":"J Genet Hum"},{"issue":"1","key":"14_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ana.410380113","volume":"38","author":"T Matilla","year":"1995","unstructured":"Matilla T, McCall A, Subramony SH et al. Molecular and clinical correlations in spinocerebellar ataxia type 3 and Machado-Joseph disease. Ann Neurol 1995; 38(1):68\u201372.","journal-title":"Ann Neurol"},{"issue":"2","key":"14_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1055\/s-2007-971172","volume":"27","author":"HL Paulson","year":"2007","unstructured":"Paulson HL. Dominantly inherited ataxias: lessons learned from Machado-Joseph disease\/spinocerebellar ataxia type 3. Semin Neurol 2007; 27(2):133\u2013142.","journal-title":"Semin Neurol"},{"issue":"2","key":"14_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12311-008-0013-4","volume":"7","author":"O Riess","year":"2008","unstructured":"Riess O, Rub U, Pastore A et al. SCA3: neurological features, pathogenesis and animal models. Cerebellum 2008; 7(2):125\u2013137.","journal-title":"Cerebellum"},{"issue":"1\u20132","key":"14_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0022-510X(02)00046-1","volume":"197","author":"E Isozaki","year":"2002","unstructured":"Isozaki E, Naito R, Kanda T et al. Different mechanism of vocal cord paralysis between spinocerebellar ataxia (SCA 1 and SCA 3) and multiple system atrophy. J Neurol Sci 2002; 197(1\u20132):37\u201343.","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"14_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jns.2004.02.014","volume":"221","author":"T Yoshizawa","year":"2004","unstructured":"Yoshizawa T, Nakamagoe K, Ueno T et al. Early vestibular dysfunction in Machado-Joseph disease detected by caloric test. J Neurol Sci 2004; 221(1\u20132):109\u2013111.","journal-title":"J Neurol Sci"},{"issue":"4","key":"14_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/archneur.62.4.630","volume":"62","author":"TH Yeh","year":"2005","unstructured":"Yeh TH, Lu CS, Chou YH et al. Autonomic dysfunction in Machado-Joseph disease. Arch Neurol 2005; 62(4):630\u2013636.","journal-title":"Arch Neurol"},{"issue":"6","key":"14_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/mds.10269","volume":"17","author":"JH Friedman","year":"2002","unstructured":"Friedman JH. Presumed rapid eye movement behavior disorder in Machado-Joseph disease (spinocerebellar ataxia type 3). Mov Disord 2002; 17(6):1350\u20131353.","journal-title":"Mov Disord"},{"issue":"12","key":"14_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/mds.10590","volume":"18","author":"JH Friedman","year":"2003","unstructured":"Friedman JH, Fernandez HH, Sudarsky LR. REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3). Mov Disord 2003; 18(12):1520\u20131522.","journal-title":"Mov Disord"},{"issue":"6","key":"14_CR12","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1212\/WNL.51.6.1603","volume":"51","author":"L Schols","year":"1998","unstructured":"Schols L, Haan J, Riess O et al. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome? Neurology 1998; 51(6):1603\u20131607.","journal-title":"Neurology"},{"issue":"6","key":"14_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ana.1089","volume":"49","author":"N Alfen van","year":"2001","unstructured":"van Alfen N, Sinke RJ, Zwarts MJ et al. Intermediate CAG repeat lengths (53,54) for MJD\/SCA3 are associated with an abnormal phenotype. Ann Neurol 2001; 49(6):805\u2013807.","journal-title":"Ann Neurol"},{"key":"14_CR14","first-page":"139","volume":"61","author":"J Sequeiros","year":"1993","unstructured":"Sequeiros J, Coutinho P. Epidemiology and clinical aspects of Machado-Joseph disease. Adv Neurol 1993; 61:139\u2013153.","journal-title":"Adv Neurol"},{"issue":"3","key":"14_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/mds.870070302","volume":"7","author":"RN Rosenberg","year":"1992","unstructured":"Rosenberg RN. Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov Disord 1992; 7(3):193\u2013203.","journal-title":"Mov Disord"},{"key":"14_CR16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1212\/WNL.28.7.703","volume":"28","author":"P Coutinho","year":"1978","unstructured":"Coutinho P, Andrade C. Autosomal dominant system degeneration in Portuguese families of the Azores Islands: a new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology 1978; 28:703\u2013709.","journal-title":"Neurology"},{"issue":"4","key":"14_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/jnnp.2004.040279","volume":"76","author":"S Yamada","year":"2005","unstructured":"Yamada S, Nishimiya J, Nakajima T et al. Linear high intensity area along the medial margin of the internal segment of the globus pallidus in Machado-Joseph disease patients. J Neurol Neurosurg Psychiatry 2005; 76(4):573\u2013575.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"14_CR18","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1093\/brain\/awf208","volume":"125","author":"U Rub","year":"2002","unstructured":"Rub U, De Vos RA, Schultz C et al. Spinocerebellar ataxia type 3 (Machado-Joseph disease): severe destruction of the lateral reticular nucleus. Brain 2002; 125:2115\u20132124.","journal-title":"Brain"},{"key":"14_CR19","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1093\/brain\/awg234","volume":"126","author":"U Rub","year":"2003","unstructured":"Rub U, Del Turco D, Del Tredici K et al. Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxia type 3 (SCA3) patient and its clinical relevance. Brain 2003; 126:2257\u20132272.","journal-title":"Brain"},{"issue":"11","key":"14_CR20","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00702-005-0287-3","volume":"112","author":"U Rub","year":"2005","unstructured":"Rub U, Gierga K, Brunt ER et al. Spinocerebellar ataxias types 2 and 3: degeneration of the precerebellar nuclei isolates the three phylogenetically defined regions of the cerebellum. J Neural Transm 2005; 112(11):1523\u20131545.","journal-title":"J Neural Transm"},{"issue":"3","key":"14_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1750-3639.2006.00022.x","volume":"16","author":"U Rub","year":"2006","unstructured":"Rub U, de Vos RA, Brunt ER et al. Spinocerebellar ataxia type 3 (SCA3): thalamic neurodegeneration occurs independently from thalamic ataxin-3 immunopositive neuronal intranuclear inclusions. Brain Pathol 2006; 16(3):218\u2013227.","journal-title":"Brain Pathol"},{"issue":"2","key":"14_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.brainresrev.2006.08.003","volume":"53","author":"U Rub","year":"2007","unstructured":"Rub U, Seidel K, Ozerden I et al. Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res Rev 2007; 53(2):235\u2013249.","journal-title":"Brain Res Rev"},{"issue":"2","key":"14_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S0891-0618(02)00099-6","volume":"25","author":"U Rub","year":"2003","unstructured":"Rub U, Brunt ER, Gierga K et al. The nucleus raphe interpositus in spinocerebellar ataxia type 3 (Machado-Joseph disease). J Chem Neuroanat 2003; 25(2):115\u2013127.","journal-title":"J Chem Neuroanat"},{"key":"14_CR24","first-page":"231","volume":"89","author":"S Tsuji","year":"2002","unstructured":"Tsuji S. Dentatorubral-pallidoluysian atrophy: clinical aspects and molecular genetics. Adv Neurol 2002; 89:231\u2013239.","journal-title":"Adv Neurol"},{"key":"14_CR25","volume-title":"GeneReviews [Internet]","author":"S Tsuji","year":"2010","unstructured":"Tsuji S. Dentatorubral-pallidoluysian atrophy In: Pagon R, Bird T, Dolan C et al, eds. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle, 2010."},{"issue":"6","key":"14_CR26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1212\/WNL.49.6.1605","volume":"49","author":"R Koide","year":"1997","unstructured":"Koide R, Onodera O, Ikeuchi T et al. Atrophy of the cerebellum and brainstem in dentatorubral pallidoluysian atrophy. Influence of CAG repeat size on MRI findings. Neurology 1997; 49(6):1605\u20131612.","journal-title":"Neurology"},{"issue":"4","key":"14_CR27","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1086\/374321","volume":"72","author":"S Jacquemont","year":"2003","unstructured":"Jacquemont S, Hagerman RJ, Leehey M et al. Fragile X premutation tremor\/ataxia syndrome: molecular, clinical and neuroimaging correlates. Am J Hum Genet 2003; 72(4):869\u2013878.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"14_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1474-4422(06)70676-7","volume":"6","author":"S Jacquemont","year":"2007","unstructured":"Jacquemont S, Hagerman RJ, Hagerman PJ et al. Fragile-X syndrome and fragile X-associated tremor\/ ataxia syndrome: two faces of FMR1. Lancet Neurol 2007; 6(1):45\u201355.","journal-title":"Lancet Neurol"},{"issue":"8","key":"14_CR29","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1212\/01.wnl.0000239837.57475.3a","volume":"67","author":"S Cohen","year":"2006","unstructured":"Cohen S, Masyn K, Adams J et al. Molecular and imaging correlates of the fragile X-associated tremor\/ ataxia syndrome. Neurology 2006; 67(8):1426\u20131431.","journal-title":"Neurology"},{"issue":"4","key":"14_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/archneur.65.4.495","volume":"65","author":"K Soontarapornchai","year":"2008","unstructured":"Soontarapornchai K, Maselli R, Fenton-Farrell G et al. Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol 2008; 65(4):495\u2013498.","journal-title":"Arch Neurol"},{"issue":"2","key":"14_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/mds.21252","volume":"22","author":"MA Leehey","year":"2007","unstructured":"Leehey MA, Berry-Kravis E, Min SJ et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 2007; 22(2):203\u2013206.","journal-title":"Mov Disord"},{"key":"14_CR32","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/brain\/awm126","volume":"130","author":"JC Jen","year":"2007","unstructured":"Jen JC, Graves TD, Hess EJ et al. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 2007; 130:2484\u20132493.","journal-title":"Brain"},{"key":"14_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1196\/annals.1444.016","volume":"1142","author":"JC Jen","year":"2008","unstructured":"Jen JC. Hereditary episodic ataxias. Ann N Y Acad Sci 2008; 1142:250\u2013253.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"14_CR34","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.neuroscience.2008.09.022","volume":"157","author":"P Imbrici","year":"2008","unstructured":"Imbrici P, Gualandi F, D'Adamo MC et al. A novel KCNA1 mutation identified in an Italian family affected by episodic ataxia type 1. Neuroscience 2008; 157(3):577\u2013587.","journal-title":"Neuroscience"},{"issue":"4","key":"14_CR35","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/1531-8249(200010)48:4<647::AID-ANA12>3.0.CO;2-Q","volume":"48","author":"LH Eunson","year":"2000","unstructured":"Eunson LH, Rea R, Zuberi SM et al. Clinical, genetic and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol 2000; 48(4):647\u2013656.","journal-title":"Ann Neurol"},{"issue":"1","key":"14_CR36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1212\/01.WNL.0000101675.61074.50","volume":"62","author":"J Jen","year":"2004","unstructured":"Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology 2004; 62(1):17\u201322.","journal-title":"Neurology"},{"issue":"11","key":"14_CR37","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/jnnp.2008.159103","volume":"80","author":"P Bertholon","year":"2009","unstructured":"Bertholon P, Chabrier S, Riant F et al. Episodic ataxia type 2: unusual aspects in clinical and genetic presentation. Special emphasis in childhood. J Neurol Neurosurg Psychiatry 2009; 80(11):1289\u20131292.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"14_CR38","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1093\/hmg\/6.11.1973","volume":"6","author":"C Jodice","year":"1997","unstructured":"Jodice C, Mantuano E, Veneziano L et al. Episodic ataxia type 2 (EA2) and spinocerebellar ataxia type 6 (SCA6) due to CAG repeat expansion in the CACNA1A gene on chromosome 19p. Hum Mol Genet 1997; 6(11):1973\u20131978.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"14_CR39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/jnnp.65.4.565","volume":"65","author":"JC Jen","year":"1998","unstructured":"Jen JC, Yue Q, Karrim J et al. Spinocerebellar ataxia type 6 with positional vertigo and acetazolamide responsive episodic ataxia. J Neurol Neurosurg Psychiatry 1998; 65(4):565\u2013568.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"14_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0092-8674(00)81373-2","volume":"87","author":"RA Ophoff","year":"1996","unstructured":"Ophoff RA, Terwindt GM, Vergouwe MN et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca(su2+)??channel gene CACNL1A4. Cell 1996; 87(3):543\u2013552.","journal-title":"Cell"},{"issue":"1","key":"14_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10048-009-0208-y","volume":"11","author":"F Riant","year":"2010","unstructured":"Riant F, Lescoat C, Vahedi K et al. Identification of CACNA1A large deletions in four patients with episodic ataxia. Neurogenetics 2010; 11(1):101\u2013106.","journal-title":"Neurogenetics"},{"issue":"8","key":"14_CR42","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1212\/WNL.57.8.1499","volume":"57","author":"JL Steckley","year":"2001","unstructured":"Steckley JL, Ebers GC, Cader MZ et al. An autosomal dominant disorder with episodic ataxia, vertigo and tinnitus. Neurology 2001; 57(8):1499\u20131502.","journal-title":"Neurology"},{"issue":"1","key":"14_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1212\/01.wnl.0000167186.05465.7c","volume":"65","author":"MZ Cader","year":"2005","unstructured":"Cader MZ, Steckley JL, Dyment DA et al. A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia. Neurology 2005; 65(1):156\u2013158.","journal-title":"Neurology"},{"key":"14_CR44","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archneur.1963.00460050021002","volume":"8","author":"TW Farmer","year":"1963","unstructured":"Farmer TW, Mustian VM. Vestibulocerebellar ataxia. A newly defined hereditary syndrome with periodic manifestations. Arch Neurol 1963; 8:471\u2013480.","journal-title":"Arch Neurol"},{"issue":"2","key":"14_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/00041327-199606000-00002","volume":"16","author":"KW Small","year":"1996","unstructured":"Small KW, Pollock SC, Vance JM et al. Ocular motility in North Carolina autosomal dominant ataxia. J Neuroophthalmol 1996; 16(2):91\u201395.","journal-title":"J Neuroophthalmol"},{"issue":"4","key":"14_CR46","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1001\/archneur.1996.00550040074016","volume":"53","author":"KF Damji","year":"1996","unstructured":"Damji KF, Allingham RR, Pollock SC et al. Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. Arch Neurol 1996; 53(4):338\u2013344.","journal-title":"Arch Neurol"},{"issue":"5","key":"14_CR47","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1086\/302909","volume":"66","author":"A Escayg","year":"2000","unstructured":"Escayg A, De Waard M, Lee DD et al. Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet 2000; 66(5):1531\u20131539.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"14_CR48","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/01.WNL.0000172638.58172.5a","volume":"65","author":"JC Jen","year":"2005","unstructured":"Jen JC, Wan J, Palos TP et al. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia and seizures. Neurology 2005; 65(4):529\u2013534.","journal-title":"Neurology"},{"issue":"1","key":"14_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/archneurol.2008.535","volume":"66","author":"B Vries de","year":"2009","unstructured":"de Vries B, Mamsa H, Stam AH et al. Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake. Arch Neurol 2009; 66(1):97\u2013101.","journal-title":"Arch Neurol"},{"issue":"5","key":"14_CR50","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/archneur.64.5.749","volume":"64","author":"KA Kerber","year":"2007","unstructured":"Kerber KA, Jen JC, Lee H et al. A new episodic ataxia syndrome with linkage to chromosome 19q13. Arch Neurol 2007; 64(5):749\u2013752.","journal-title":"Arch Neurol"},{"issue":"3","key":"14_CR51","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1086\/338933","volume":"70","author":"IA Meijer","year":"2002","unstructured":"Meijer IA, Hand CK, Grewal KK et al. A locus for autosomal dominant hereditary spastic ataxia, sax1, maps to chromosome 12p13. Am J Hum Genet 2002; 70(3):763\u2013769.","journal-title":"Am J Hum Genet"},{"issue":"1\u20132","key":"14_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0022-510X(95)00228-0","volume":"134","author":"A Melberg","year":"1995","unstructured":"Melberg A, Hetta J, Dahl N et al. Autosomal dominant cerebellar ataxia deafness and narcolepsy. J Neurol Sci 1995; 134(1\u20132):119\u2013129.","journal-title":"J Neurol Sci"},{"issue":"9","key":"14_CR53","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1212\/WNL.53.9.2190","volume":"53","author":"A Melberg","year":"1999","unstructured":"Melberg A, Dahl N, Hetta J et al. Neuroimaging study in autosomal dominant cerebellar ataxia, deafness and narcolepsy. Neurology 1999; 53(9):2190\u20132192.","journal-title":"Neurology"},{"issue":"6","key":"14_CR54","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1136\/jmg.2005.035667","volume":"43","author":"MM Trudeau","year":"2006","unstructured":"Trudeau MM, Dalton JC, Day JW et al. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia and mental retardation. J Med Genet 2006; 43(6):527\u2013530.","journal-title":"J Med Genet"},{"issue":"5","key":"14_CR55","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/jnnp.2008.151548","volume":"80","author":"D Genis","year":"2009","unstructured":"Genis D, Ferrer I, Sole JV et al. A kindred with cerebellar ataxia and thermoanalgesia. J Neurol Neurosurg Psychiatry 2009; 80(5):518\u2013523.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"14_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/147342204100032331","volume":"3","author":"M Ogawa","year":"2004","unstructured":"Ogawa M. Pharmacological treatments of cerebellar ataxia. Cerebellum 2004; 3(2):107\u2013111.","journal-title":"Cerebellum"},{"issue":"4","key":"14_CR57","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/WCO.0b013e32832b9897","volume":"22","author":"M Manto","year":"2009","unstructured":"Manto M, Marmolino D. Cerebellar ataxias. Curr Opin Neurol 2009; 22(4):419\u2013429.","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"14_CR58","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/mds.22564","volume":"24","author":"MM Trujillo-Martin","year":"2009","unstructured":"Trujillo-Martin MM, Serrano-Aguilar P, Monton-Alvarez F et al. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord 2009; 24(8):1111\u20131124.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"14_CR59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jns.2008.12.017","volume":"278","author":"K Nakamura","year":"2009","unstructured":"Nakamura K, Yoshida K, Miyazaki D et al. Spinocerebellar ataxia type 6 (SCA6): clinical pilot trial with gabapentin. J Neurol Sci 2009; 278(1\u20132):107\u2013111.","journal-title":"J Neurol Sci"},{"issue":"2","key":"14_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0022-510X(72)90137-2","volume":"17","author":"BT Woods","year":"1972","unstructured":"Woods BT, Schaumburg HH. Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia. A unique and partially treatable clinicopathological entity. J Neurol Sci 1972; 17(2):149\u2013166.","journal-title":"J Neurol Sci"},{"issue":"4","key":"14_CR61","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/ana.410380422","volume":"38","author":"PJ Tuite","year":"1995","unstructured":"Tuite PJ, Rogaeva EA, St George-Hyslop PH et al. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 1995; 38(4):684\u2013687.","journal-title":"Ann Neurol"},{"issue":"2","key":"14_CR62","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mds.10322","volume":"18","author":"C Buhmann","year":"2003","unstructured":"Buhmann C, Bussopulos A, Oechsner M. Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord 2003; 18(2):219\u2013221.","journal-title":"Mov Disord"},{"key":"14_CR63","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/brain\/awg073","volume":"126","author":"K Kanai","year":"2003","unstructured":"Kanai K, Kuwabara S, Arai K et al. Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 2003; 126:965\u2013973.","journal-title":"Brain"},{"issue":"9","key":"14_CR64","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/mds.23129","volume":"25","author":"M Pineda","year":"2010","unstructured":"Pineda M, Montero R, Aracil A et al. Coenzyme Q(10)-responsive ataxia: 2-Year-treatment follow-up. Mov Disord 2010; 25(9):1262\u20138.","journal-title":"Mov Disord"},{"issue":"11\u201312","key":"14_CR65","first-page":"589","volume":"52","author":"RJ Lock","year":"2006","unstructured":"Lock RJ, Tengah DP, Williams AJ et al. Cerebellar ataxia, peripheral neuropathy, \u201cgluten sensitivity\u201d and anti-neuronal autoantibodies. Clin Lab 2006; 52(11\u201312):589\u2013592.","journal-title":"Clin Lab"},{"issue":"10","key":"14_CR66","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2169\/internalmedicine.48.1802","volume":"48","author":"K Nanri","year":"2009","unstructured":"Nanri K, Okita M, Takeguchi M et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med 2009; 48(10):783\u2013790.","journal-title":"Intern Med"},{"issue":"8","key":"14_CR67","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/nm1076","volume":"10","author":"H Xia","year":"2004","unstructured":"Xia H, Mao Q, Eliason SL et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10(8):816\u2013820.","journal-title":"Nat Med"},{"issue":"1","key":"14_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrn1587","volume":"6","author":"PJ Muchowski","year":"2005","unstructured":"Muchowski PJ, Wacker JL. Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 2005; 6(1):11\u201322.","journal-title":"Nat Rev Neurosci"},{"issue":"19","key":"14_CR69","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1093\/hmg\/9.19.2811","volume":"9","author":"HY Chan","year":"2000","unstructured":"Chan HY, Warrick JM, Gray-Board GL et al. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet 2000; 9(19):2811\u20132820.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"14_CR70","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.1073\/pnas.110138997","volume":"97","author":"V Heiser","year":"2000","unstructured":"Heiser V, Scherzinger E, Boeddrich A et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington\u2019s disease therapy. Proc Natl Acad Sci USA 2000; 97(12):6739\u20136744.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6921","key":"14_CR71","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature01301","volume":"421","author":"I Sanchez","year":"2003","unstructured":"Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003; 421(6921):373\u2013379.","journal-title":"Nature"},{"issue":"2","key":"14_CR72","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1006\/nbdi.2002.0502","volume":"10","author":"H Yoshida","year":"2002","unstructured":"Yoshida H, Yoshizawa T, Shibasaki F et al. Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol Dis 2002; 10(2):88\u201399.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"14_CR73","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nm985","volume":"10","author":"M Tanaka","year":"2004","unstructured":"Tanaka M, Machida Y, Niu S et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004; 10(2):148\u2013154.","journal-title":"Nat Med"},{"key":"14_CR74","doi-asserted-by":"publisher","first-page":"16400","DOI":"10.1073\/pnas.182426599","volume":"99","author":"V Heiser","year":"2002","unstructured":"Heiser V, Engemann S, Brocker W et al. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington\u2019s disease by using an automated filter retardation assay. Proc Natl Acad Sci USA 2002; 99:16400\u201316406.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"14_CR75","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1073\/pnas.0408936102","volume":"102","author":"X Zhang","year":"2005","unstructured":"Zhang X, Smith DL, Meriin AB et al. A potent small molecule inhibits polyglutamine aggregation in Huntington\u2019s disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci USA 2005; 102(3):892\u2013897.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"14_CR76","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nm1021","volume":"10","author":"D Kieran","year":"2004","unstructured":"Kieran D, Kalmar B, Dick JR et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004; 10(4):402\u2013405.","journal-title":"Nat Med"},{"issue":"3\u20134","key":"14_CR77","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0361-9230(01)00602-5","volume":"56","author":"M Rimoldi","year":"2001","unstructured":"Rimoldi M, Servadio A, Zimarino V. Analysis of heat shock transcription factor for suppression of polyglutamine toxicity. Brain Res Bull 2001; 56(3\u20134):353\u2013362.","journal-title":"Brain Res Bull"},{"issue":"16","key":"14_CR78","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1038\/sj.onc.1207529","volume":"23","author":"DD Mosser","year":"2004","unstructured":"Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004; 23(16):2907\u20132918.","journal-title":"Oncogene"},{"issue":"20","key":"14_CR79","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","volume":"22","author":"A Dedeoglu","year":"2002","unstructured":"Dedeoglu A, Kubilus JK, Jeitner TM et al. Therapeutic effects of cystamine in a murine model of Huntington\u2019s disease. J Neurosci 2002; 22(20):8942\u20138950.","journal-title":"J Neurosci"},{"issue":"2","key":"14_CR80","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm0202-143","volume":"8","author":"MV Karpuj","year":"2002","unstructured":"Karpuj MV, Becher MW, Springer JE et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002; 8(2):143\u2013149.","journal-title":"Nat Med"},{"issue":"19","key":"14_CR81","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2174\/0929867033456882","volume":"10","author":"CW Shults","year":"2003","unstructured":"Shults CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003; 10(19):1917\u20131921.","journal-title":"Curr Med Chem"},{"issue":"2","key":"14_CR82","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pharmthera.2005.04.008","volume":"108","author":"H Ryu","year":"2005","unstructured":"Ryu H, Rosas HD, Hersch SM et al. The therapeutic role of creatine in Huntington\u2019s disease. Pharmacol Ther 2005; 108(2):193\u2013207.","journal-title":"Pharmacol Ther"},{"issue":"16","key":"14_CR83","doi-asserted-by":"publisher","first-page":"10671","DOI":"10.1073\/pnas.162362299","volume":"99","author":"CD Keene","year":"2002","unstructured":"Keene CD, Rodrigues CM, Eich T et al. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington\u2019s disease. Proc Natl Acad Sci USA 2002; 99(16):10671\u201310676.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"14_CR84","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar B, Vacher C, Berger Z et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36(6):585\u2013595.","journal-title":"Nat Genet"},{"issue":"2","key":"14_CR85","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4161\/auto.6.2.11078","volume":"6","author":"FM Menzies","year":"2010","unstructured":"Menzies FM, Rubinsztein DC. Broadening the therapeutic scope for rapamycin treatment. Autophagy 2010; 6(2):286\u2013287.","journal-title":"Autophagy"},{"issue":"3","key":"14_CR86","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0896-6273(00)80716-3","volume":"22","author":"I Sanchez","year":"1999","unstructured":"Sanchez I, Xu CJ, Juo P et al. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999; 22(3):623\u2013633.","journal-title":"Neuron"},{"issue":"6733","key":"14_CR87","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/20446","volume":"399","author":"VO Ona","year":"1999","unstructured":"Ona VO, Li M, Vonsattel JP et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington\u2019s disease. Nature 1999; 399(6733):263\u2013267.","journal-title":"Nature"},{"issue":"7","key":"14_CR88","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/77528","volume":"6","author":"M Chen","year":"2000","unstructured":"Chen M, Ona VO, Li M et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6(7):797\u2013801.","journal-title":"Nat Med"},{"issue":"6","key":"14_CR89","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1074\/jbc.M205812200","volume":"278","author":"M Lesort","year":"2003","unstructured":"Lesort M, Lee M, Tucholski J et al. Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem 2003; 278(6):3825\u20133830.","journal-title":"J Biol Chem"},{"issue":"1","key":"14_CR90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/ebmh.12.1.21","volume":"12","author":"S Gauthier","year":"2009","unstructured":"Gauthier S. Dimebon improves cognitive function in people with mild to moderate Alzheimer\u2019s disease. Evid Based Ment Health 2009; 12(1):21.","journal-title":"Evid Based Ment Health"},{"issue":"29","key":"14_CR91","doi-asserted-by":"publisher","first-page":"9148","DOI":"10.1523\/JNEUROSCI.0660-09.2009","volume":"29","author":"J Liu","year":"2009","unstructured":"Liu J, Tang TS, Tu H et al. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. J Neurosci 2009; 29(29):9148\u20139162.","journal-title":"J Neurosci"},{"key":"14_CR92","first-page":"CD006455","volume":"3","author":"T Mestre","year":"2009","unstructured":"Mestre T, Ferreira J, Coelho MM et al. Therapeutic interventions for disease progression in Huntington\u2019s disease. Cochrane Database Syst Rev 2009; 3:CD006455.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"14_CR93","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1212\/WNL.0b013e3181d31e23","volume":"74","author":"G Ristori","year":"2010","unstructured":"Ristori G, Romano S, Visconti A et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010; 74(10):839\u2013845.","journal-title":"Neurology"},{"issue":"2","key":"14_CR94","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1124\/jpet.107.123000","volume":"322","author":"T Bordet","year":"2007","unstructured":"Bordet T, Buisson B, Michaud M et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007; 322(2):709\u2013720.","journal-title":"J Pharmacol Exp Ther"},{"key":"14_CR95","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0079-6123(08)00676-6","volume":"171","author":"M Strupp","year":"2008","unstructured":"Strupp M, Kalla R, Glasauer S et al. Aminopyridines for the treatment of cerebellar and ocular motor disorders. Prog Brain Res 2008; 171:535\u2013541.","journal-title":"Prog Brain Res"},{"issue":"21","key":"14_CR96","doi-asserted-by":"publisher","first-page":"7258","DOI":"10.1523\/JNEUROSCI.3582-09.2010","volume":"30","author":"K Alvina","year":"2010","unstructured":"Alvina K, Khodakhah K. The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. J Neurosci 2010; 30(21):7258\u20137268.","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"14_CR97","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jns.2010.01.021","volume":"292","author":"T Tsunemi","year":"2010","unstructured":"Tsunemi T, Ishikawa K, Tsukui K et al. The effect of 3,4-diaminopyridine on the patients with hereditary pure cerebellar ataxia. J Neurol Sci 2010; 292(1\u20132):81\u201384.","journal-title":"J Neurol Sci"},{"issue":"2","key":"14_CR98","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/jcb.20532","volume":"96","author":"M Dokmanovic","year":"2005","unstructured":"Dokmanovic M, Marks PA. Prospects: Histone deacetylase inhibitors. J Cell Biochem 2005; 96(2):293\u2013304.","journal-title":"J Cell Biochem"},{"issue":"40","key":"14_CR99","doi-asserted-by":"publisher","first-page":"15564","DOI":"10.1073\/pnas.0804249105","volume":"105","author":"EA Thomas","year":"2008","unstructured":"Thomas EA, Coppola G, Desplats PA et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice. Proc Natl Acad Sci USA 2008; 105(40):15564\u201315569.","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR100","doi-asserted-by":"crossref","unstructured":"Naoi M, Maruyama W, Yi H et al. Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm 2009.","DOI":"10.1007\/s00702-009-0309-7"},{"issue":"4","key":"14_CR101","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1073\/pnas.0711257105","volume":"105","author":"JR Gatchel","year":"2008","unstructured":"Gatchel JR, Watase K, Thaller C et al. The insulin-like growth factor pathway is altered in spinocerebellar ataxia type 1 and type 7. Proc Natl Acad Sci USA 2008; 105(4):1291\u20131296.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"14_CR102","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.brainresrev.2005.05.003","volume":"50","author":"AM Fernandez","year":"2005","unstructured":"Fernandez AM, Carro EM, Lopez-Lopez C et al. Insulin-like growth factor I treatment for cerebellar ataxia: Addressing a common pathway in the pathological cascade? Brain Res Rev 2005; 50(1):134\u2013141.","journal-title":"Brain Res Rev"},{"key":"14_CR103","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000085763","volume":"9","author":"GM Leinninger","year":"2005","unstructured":"Leinninger GM, Feldman EL. Insulin-like growth factors in the treatment of neurological disease. Endocr Dev 2005; 9:135\u2013159.","journal-title":"Endocr Dev"},{"issue":"42","key":"14_CR104","doi-asserted-by":"publisher","first-page":"13126","DOI":"10.1523\/JNEUROSCI.0647-09.2009","volume":"29","author":"S Chintawar","year":"2009","unstructured":"Chintawar S, Hourez R, Ravella A et al. Grafting neural precursor cells promotes functional recovery in an SCA1 mouse model. J Neurosci 2009; 29(42):13126\u201313135.","journal-title":"J Neurosci"},{"issue":"3","key":"14_CR105","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1523\/JNEUROSCI.22-03-00612.2002","volume":"22","author":"FH Gage","year":"2002","unstructured":"Gage FH. Neurogenesis in the adult brain. J Neurosci 2002; 22(3):612\u2013613.","journal-title":"J Neurosci"},{"issue":"2","key":"14_CR106","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-2004-817921","volume":"35","author":"A Klein","year":"2004","unstructured":"Klein A, Boltshauser E, Jen J et al. Episodic ataxia type 1 with distal weakness: a novel manifestation of a potassium channelopathy. Neuropediatrics 2004; 35(2):147\u2013149.","journal-title":"Neuropediatrics"},{"issue":"12","key":"14_CR107","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1212\/WNL.28.12.1259","volume":"28","author":"RC Griggs","year":"1978","unstructured":"Griggs RC, Moxley RT, 3rd, Lafrance RA et al. Hereditary paroxysmal ataxia: response to acetazolamide. Neurology 1978; 28(12):1259\u20131264.","journal-title":"Neurology"},{"issue":"4","key":"14_CR108","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1055\/s-2008-1052450","volume":"19","author":"M Boel","year":"1988","unstructured":"Boel M, Casaer P. Familial periodic ataxia responsive to flunarizine. Neuropediatrics 1988; 19(4):218\u2013220.","journal-title":"Neuropediatrics"},{"issue":"9","key":"14_CR109","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1212\/01.WNL.0000125691.74109.53","volume":"62","author":"M Strupp","year":"2004","unstructured":"Strupp M, Kalla R, Dichgans M et al. Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 2004; 62(9):1623\u20131625.","journal-title":"Neurology"},{"issue":"21","key":"14_CR110","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.1523\/JNEUROSCI.6341-09.2010","volume":"30","author":"K Alvina","year":"2010","unstructured":"Alvina K, Khodakhah K. KCa channels as therapeutic targets in episodic ataxia type-2. J Neurosci 2010; 30(21):7249\u20137257.","journal-title":"J Neurosci"},{"issue":"10","key":"14_CR111","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.nmd.2004.06.007","volume":"14","author":"M Kinali","year":"2004","unstructured":"Kinali M, Jungbluth H, Eunson LH et al. Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia. Neuromuscul Disord 2004; 14(10):689\u2013693.","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"14_CR112","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1059-1311(02)00267-4","volume":"12","author":"FA Marcos De","year":"2003","unstructured":"De Marcos FA, Ghizoni E, Kobayashi E et al. Cerebellar volume and long-term use of phenytoin. Seizure 2003; 12(5):312\u2013315.","journal-title":"Seizure"},{"issue":"2","key":"14_CR113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1212\/01.WNL.0000078893.41040.56","volume":"61","author":"M Strupp","year":"2003","unstructured":"Strupp M, Schuler O, Krafczyk S et al. Treatment of down-beat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology 2003; 61(2):165\u2013170.","journal-title":"Neurology"},{"issue":"22","key":"14_CR114","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1212\/WNL.0b013e3181c33adf","volume":"73","author":"W Ilg","year":"2009","unstructured":"Ilg W, Synofzik M, Brotz D et al. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 2009; 73(22):1823\u20131830.","journal-title":"Neurology"},{"issue":"4\u20135","key":"14_CR115","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.neucli.2009.07.002","volume":"39","author":"B Missaoui","year":"2009","unstructured":"Missaoui B, Thoumie P. How far do patients with sensory ataxia benefit from so-called \u201cproprioceptive rehabilitation\u201d? Neurophysiol Clin 2009; 39(4\u20135):229\u2013233.","journal-title":"europhysiol Clin"}],"container-title":["Advances in Experimental Medicine and Biology","Neurodegenerative Diseases"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4614-0653-2_14.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T08:41:25Z","timestamp":1619858485000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4614-0653-2_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"ISBN":["9781461406525","9781461406532"],"references-count":115,"URL":"https:\/\/doi.org\/10.1007\/978-1-4614-0653-2_14","relation":{},"ISSN":["0065-2598"],"issn-type":[{"value":"0065-2598","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}